Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Multiple Paths of Convergence in Tissue Engineering

This article was originally published in Start Up

Executive Summary

A collaboration within Carnegie Mellon is using ink-jet printing technology to create spatial patterns of growth factors, and in turn using them to influence the development of stem cells in vitro. The technology could provide a better means of harnessing the power of growth factor biology in regenerative medicine. The team is also using it to begin to develop rudimentary artificial bone-tendon-muscle constructs for eventual clinical use.

You may also be interested in...

Start-Up News February 2008

Noteworthy news from medtech start-ups. In this issue: New Scaffolds for Tissue Engineering, with brief profiles of BioCeramic Therapeutics Ltd., Histogen Inc., Humacyte Inc., and Tissue Regenix. (Adapted from "Scaffolds in Tissue Engineering," START-UP, February 2008.)

Scaffolds in Tissue Engineering

Stem-cell-related strategies may predominate these days in tissue engineering, but cell therapy companies know that providing the right microenvironment for nurturing tissue growth remains a difficult and essential challenge. Thus, start-ups remain committed to the developent of cellular matrices that provide the appropriate structure, environment, and bioactivity to encourage tissue growth. The four start-ups profiled in this issue represent a cross-section of strategies.

Timing the Stem Cell Opportunity

Companies are drawing parallels between the monoclonal antibody industry and stem cells, and they are trying to strike a balance between gaining a stake in a field with tremendous potential without being too early. Stem cells have the potential to treat some of the largest degenerative diseases in the cardiovascular, neurological, orthopedic segments--markets worth in the double digit billions, according to a recent report on Tissue Engineering, issued by Medtech Insight. No company wants to be left behind.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts